X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 10, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
November 09, 2023 06:01 ET
|
X4 Pharmaceuticals
U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if...
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
November 02, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
October 31, 2023 08:00 ET
|
X4 Pharmaceuticals
FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024 If the NDA is approved, company eligible to receive a Priority Review Voucher (PRV) resulting from mavorixafor’s...
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
October 18, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...
X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...